Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neo-adjuvant Treatment of Glioblastomas With Marked to Severe Neurological Impairment Using Upfront Bevacizumab/témozolomide Association Before an Eventual Radiotherapy. Multicentric Phase II Study

NCT03623347 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire, Amiens as lead sponsor.

NCT NCT03623347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03623347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neo-adjuvant Treatment of Glioblastomas With Marked to Severe Neurological Impairment Using Upfront Bevacizumab/témozolomide Association Before an Eventual Radiotherapy. Multicentric Phase II Study
Lead sponsor
Centre Hospitalier Universitaire, Amiens
Phase
Observational
Overall status
Completed
Start date
January 1, 2011
Completion date
May 12, 2017
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemoradiotherapy